Advertisement
Advertisement
BCYC
Bicycle Therapeutics plc - ADR
4.50
USDSponsored
-0.18
-3.85%
Mar 26, 15:59 UTC -4
Closed
Pre-Market
4.74
+0.24
+5.40%
BCYC Earnings Reports
Positive Surprise Ratio
BCYC beat 13 of 27 last estimates.
48%
Next Report
Date of Next Report
Apr 29, 2026
Estimate for Q1 26 (Revenue/ EPS)
$8.96M
/-$0.69
Implied change from Q4 25 (Revenue/ EPS)
-81.31%
/+146.43%
Implied change from Q1 25 (Revenue/ EPS)
-10.16%
/-21.59%
Bicycle Therapeutics plc - ADR earnings per share and revenue
On Mar 17, 2026, BCYC reported earnings of -0.28 USD per share (EPS) for Q4 25, beating the estimate of -0.95 USD, resulting in a 69.66% surprise. Revenue reached 47.95 million, compared to an expected 7.22 million, with a 564.65% difference. The market reacted with a +3.31% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 7 analysts forecast an EPS of -0.69 USD, with revenue projected to reach 8.96 million USD, implying an increase of 146.43% EPS, and decrease of -81.31% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
Acumen Pharmaceuticals, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.46
Actual
-$0.41
Surprise
+11.29%
Rani Therapeutics Holdings, Inc. Class A Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.07
Surprise
-2.94%
Spero Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.20
Actual
$0.53
Surprise
+359.80%
Alpha Cognition Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.30
Surprise
-8.93%
Cognition Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.02
Surprise
+76.47%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
Quantum Biopharma Ltd. Class B Subordinate Voting Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-Actual
-$0.71
Surprise
-
CollPlant Biotechnologies Ltd Ordinary Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.67
Surprise
-245.72%
FAQ
What were Bicycle Therapeutics plc - ADR's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Bicycle Therapeutics plc - ADR reported EPS of -$0.28, beating estimates by 69.66%, and revenue of $47.95M, 564.65% above expectations.
How did the market react to Bicycle Therapeutics plc - ADR's Q4 2025 earnings?
The stock price moved up 3.31%, changed from $5.44 before the earnings release to $5.62 the day after.
When is Bicycle Therapeutics plc - ADR expected to report next?
The next earning report is scheduled for Apr 29, 2026.
What are the forecasts for Bicycle Therapeutics plc - ADR's next earnings report?
Based on 7
analysts, Bicycle Therapeutics plc - ADR is expected to report EPS of -$0.69 and revenue of $8.96M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement